Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Picked up more today.
Time will tell...
I started buying today. Looking for $1
I bought in today. Now I’ll sit and wait.
EYEN..........................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783
EYEN.......................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783
EYEN --
--Northland Adjusts Eyenovia's Price Target to $9 From $12, Maintains Outperform Rating
BY MT Newswires
— 9:31 AM ET 10/26/2021
* * $EYEN Video Chart 08-11-2020 * *
Link to Video - click here to watch the technical chart video
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
8:05 am ET August 11, 2020 (Globe Newswire) Print
Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs
Arctic Vision to Lead Expansion of Novel Approach to Treating Myopia and Presbyopia in Greater China and South Korea
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP(TM)) therapeutics and Arctic Vision, a clinical stage biotech company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, today announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
Under the terms of the agreement, Eyenovia may receive up to a total of $45.75 million in upfront payments as well as additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. In addition, Arctic Vision will purchase its supply of MicroPine and MicroLine from Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. Eyenovia will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to its Asian licensee pursuant to the arrangement
anyone who sees the video of the kid using the machine will buy the stock.
So easy and simple to use-REVOLUTIONARY. Very impressive.
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
looks like next breakout about to start
STRONG BUY this pure undiscovered Goldmine
Down a lot today. I'd say related to ALDX (another "eyes" biotech) which is down about 32% following Top-Line results. It's a mistake to associate the faith of those 2 IMO. This is creating a great opportunity. Will go back over 4$ very soon and may never "look" back. This wild horse will suddenly run free at some point. Great MGT. Founder keeps on buying. Great innovation. First-in-class comes to mind.
4 years from now 300 dollar stock when myopia drug approved
UUUUUUUUUUUUUUUUUUUP again and still terrible undervalued
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
$20 stock trading at $3
mega potential here
could run fast
200k day, crazy trading swings. should be volume reversal, we shall see.
Company is a conduit for drug delivery for every topical eye care drug company in existence, and hence will be bought out.
Game of Rogues- 40 cent spread between bid and asked, no law in the Wild West.
The undiscovered country.
This is going to be the new application standard for all things eye.
One machine with multi-function use.
Enormous market. one of a kind tech with no competition, as they lead with multiple phase 3 trials, and small cap equals grand slam home run.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
47
|
Created
|
12/28/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |